APA (7th ed.) Citation

Pérol, M., Ciuleanu, T., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., . . . Thomas, M. (2016). Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung cancer, 93, . https://doi.org/10.1016/j.lungcan.2016.01.007

Chicago Style (17th ed.) Citation

Pérol, Maurice, et al. "Quality of Life Results from the Phase 3 REVEL Randomized Clinical Trial of Ramucirumab-plus-docetaxel Versus Placebo-plus-docetaxel in Advanced/metastatic Non-small Cell Lung Cancer Patients with Progression After Platinum-based Chemotherapy." Lung Cancer 93 (2016). https://doi.org/10.1016/j.lungcan.2016.01.007.

MLA (9th ed.) Citation

Pérol, Maurice, et al. "Quality of Life Results from the Phase 3 REVEL Randomized Clinical Trial of Ramucirumab-plus-docetaxel Versus Placebo-plus-docetaxel in Advanced/metastatic Non-small Cell Lung Cancer Patients with Progression After Platinum-based Chemotherapy." Lung Cancer, vol. 93, 2016, https://doi.org/10.1016/j.lungcan.2016.01.007.